References
Pospisilova H, Baens M, Michaux L, Stul M, Van Hummelen P, Van Loo P et al. Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL. Leukemia 2007; 21: 2079–2083.
Tilly H, Bastard C, Halkin E, Lenormand B, Bizet M, Dauce JP et al. Del(14)(q22) in diffuse B-cell lymphocytic lymphoma. Am J Clin Pathol 1988; 89: 109–113.
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115–130.
Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131–144.
Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom′s macroglobulinemia. Cancer Res 2009; 69: 3579–3588.
Xie P, Stunz LL, Larison KD, Yang B, Bishop GA . Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007; 27: 253–267.
He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G . Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem 2007; 282: 3688–3694.
Basseres DS, Baldwin AS . Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25: 6817–6830.
Acknowledgements
We gratefully thank Kerstin Runde, Reina Zühlke-Jenisch, Magret Ratjen, Dorit Schuster, Claudia Becher and Ursula Schnaidt for their technical assistance. Supported by the Network Project of the Deutsche Krebshilfe ‘Molecular Mechanisms in Malignant Lymphomas’ 70-3173-TR3, the Wilhelm Sander-Stiftung 2005.168.2 and RETICS. Instituto de Salud Carlos III, RETICS. Convocatoria 2008. RD07/0020/2004.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Rights and permissions
About this article
Cite this article
Nagel, I., Bug, S., Tönnies, H. et al. Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia 23, 2153–2155 (2009). https://doi.org/10.1038/leu.2009.149
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.149
- Springer Nature Limited
This article is cited by
-
TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs
Cell Death & Disease (2023)
-
Structural feature of TRAFs, their related human diseases and therapeutic intervention
Archives of Pharmacal Research (2021)
-
TGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis
Nature Communications (2019)
-
Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes
Journal of Hematology & Oncology (2014)
-
N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma
BMC Cancer (2013)